We Proved Patient-Centric Trials Worked. Why Did We Stop Using Them?
In person exclusive panel and networking evening
The COVID-19 pandemic proved that clinical trials could be delivered differently. Decentralized, hybrid, and community-based models helped bring research closer to patients, improve access, and maintain study quality.
Yet despite these successes, much of the industry has since shifted back toward traditional, site-centric models. With enrollment challenges still delaying timelines and increasing costs, there is a growing need to rethink how patient access is built into clinical development from the very beginning.
Join us for a dynamic panel discussion exploring how early cross-functional collaboration — especially between medical, clinical, and commercial teams — can unlock value, accelerate inflection points, and build a foundation for long-term growth.
In this panel, experts will dive deeper into:
- Why the industry has returned to site-centric research despite the success of patient-centric trial models
- How evolving regulatory guidance continues to support more patient-centric approaches
- Why patient access should be treated as a clinical development strategy—not just an enrollment tactic
- Practical lessons for integrating decentralized, hybrid, and community-based models into future studies
- How reducing operational barriers can improve trial performance and patient access
Speakers
Kenneth Getz
Executive Director, Research Professor
Tufts Center for the
Study of Drug Development
Enjoy the Evening
6:00pm – 6:15pm
Arrival & Networking
(Drinks & Hors d’Oeuvres will be served)
6:15pm – 7:15pm
Panel Discussion
7:15pm - 8:30pm
Post Panel Networking Drinks
(further Hors d’Oeuvres and sweet treats)
GETTING THERE
(only 2 min walk from conference venue)
Four Seasons Hotel, One Dalton Street
This private event is being held on the 3rd floor in the Clarendon Ballroom of the Four Seasons Hotel
